Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
Source link
Similar Posts
SHUBH MAHASHIVRATRI 2026
DISCLAIMER:- Investing in any equity is risky. Our recommendations are based on reliable sources believed to be true & correct, and also is technical analysis based on & conceived from charts.The information provided is not guaranteed as to accuracy or completeness. All investors should consult a qualified professional before trading any stock or Investors should…
Hind Copper: Lohum Lao
Source: Exchange Filings of Hindustan Copper Ltd Source link
Rolling Up vs. Trailing Stops (Preview)
By Lawrence G. McMillan In The Option Strategist Newsletter, we recently had a very nice profit on a long run by the Silver ETF (SLV). We rolled that position seven times, each time taking a credit from selling a relatively deeply in-the-money call option and replacing it with an at-the-money call. There are a few…
AST SpaceMobile to revolutionize smartphones—Early September launch and strategic partnerships have investors buzzing 📲
On August 15, 2024, AST SpaceMobile’s stock saw a significant increase, driven by several key factors. The company… This article AST SpaceMobile to revolutionize smartphones—Early September launch and strategic partnerships have investors buzzing 📲 appeared first on Guerilla Stock Trading. Source link
Lupin Shares Trade Flat on USFDA Approval – Equitypandit
Shares of Lupin Ltd were trading flat on 9 May after the company announced securing approval from the United States Food and Drug Administration (USFDA) for Raltegravir Tablets. In its regulatory filing, the company said, “The company. has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application…
